Know Cancer

or
forgot password

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting


Phase 3
18 Years
N/A
Open (Enrolling)
Both
HER2+ Metastatic Breast Cancer (MBC)

Thank you

Trial Information

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting


This is a randomized, multi-center, multinational, open-label, active-controlled, parallel
design study of the combination of neratinib plus capecitabine versus the combination of
lapatinib plus capecitabine in HER2+ MBC patients who have received two or more prior HER2
directed regimens in the metastatic setting. Patients will be randomized in a 1:1 ratio to
one of the following treatment arms:

- Arm A: neratinib (240 mg once daily) + capecitabine (1500 mg/m^2 daily, 750 mg/m^2
twice daily [BID])

- Arm B: lapatinib (1250 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2
BID)

Patients will receive either neratinib plus capecitabine combination or lapatinib plus
capecitabine combination until the occurrence of death, disease progression, unacceptable
toxicity, or other specified withdrawal criterion.


Inclusion Criteria:



- Aged ≥18 years at signing of informed consent.

- Histologically confirmed MBC, current stage IV.

- Documented HER2 overexpression or gene-amplified tumor (immunohistochemistry [IHC] 3+
or IHC 2+ with confirmatory fluorescence in situ hybridization [FISH]+).

- Prior treatment with at least two (2) HER2-directed regimens for metastatic breast
cancer.

Exclusion Criteria:

- Received previous therapy with capecitabine, neratinib, lapatinib, or any other HER2
directed tyrosine kinase inhibitor.

Note: There are additional inclusion and exclusion criteria. The study center will
determine if you meet all of the criteria.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Independently assessed Progression Free Survival

Outcome Time Frame:

Estimated 10 months

Safety Issue:

No

Authority:

United States: Food and Drug Administration

Study ID:

PUMA-NER-1301

NCT ID:

NCT01808573

Start Date:

March 2013

Completion Date:

May 2018

Related Keywords:

  • HER2+ Metastatic Breast Cancer (MBC)
  • Breast Neoplasms

Name

Location

Beaver Medical Group Highland, California  92346
Innovative Clinical Research Institute Downey, California  90241
East Valley Hematology Oncology Med Group Burbank, California  
Marin General Hospital - Marin Cancer Institute Marin, California  
Orchard Research Healthcare Skokie, Illinois